Mengyang Di

1.2k total citations
54 papers, 770 citations indexed

About

Mengyang Di is a scholar working on Oncology, Pathology and Forensic Medicine and Surgery. According to data from OpenAlex, Mengyang Di has authored 54 papers receiving a total of 770 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 13 papers in Pathology and Forensic Medicine and 9 papers in Surgery. Recurrent topics in Mengyang Di's work include Lymphoma Diagnosis and Treatment (12 papers), Chronic Lymphocytic Leukemia Research (6 papers) and CAR-T cell therapy research (5 papers). Mengyang Di is often cited by papers focused on Lymphoma Diagnosis and Treatment (12 papers), Chronic Lymphocytic Leukemia Research (6 papers) and CAR-T cell therapy research (5 papers). Mengyang Di collaborates with scholars based in United States, China and Hong Kong. Mengyang Di's co-authors include Zu‐Yao Yang, Scott F. Huntington, Chen Mao, Jinling Tang, Adam J. Olszewski, Gaelen P. Adam, Thomas A Trikalinos, Dayong Zheng, Qing Chen and Yafang Huang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Annals of Internal Medicine.

In The Last Decade

Mengyang Di

44 papers receiving 763 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mengyang Di United States 15 303 204 129 127 119 54 770
Deniz Tural Türkiye 17 478 1.6× 217 1.1× 116 0.9× 377 3.0× 89 0.7× 121 938
Shu Wang China 17 202 0.7× 237 1.2× 98 0.8× 245 1.9× 77 0.6× 78 818
Jonathan Klein United States 14 199 0.7× 215 1.1× 80 0.6× 247 1.9× 113 0.9× 40 900
Eun‐Kee Song South Korea 22 623 2.1× 277 1.4× 245 1.9× 380 3.0× 86 0.7× 80 1.4k
Enes Erul Türkiye 11 304 1.0× 94 0.5× 119 0.9× 155 1.2× 82 0.7× 34 610
Mustafa Erman Türkiye 18 401 1.3× 94 0.5× 124 1.0× 271 2.1× 118 1.0× 117 1.0k
Vincenzo Montesarchio Italy 17 373 1.2× 108 0.5× 155 1.2× 229 1.8× 113 0.9× 69 847
Vivek Kumar United States 16 733 2.4× 172 0.8× 126 1.0× 190 1.5× 207 1.7× 63 1.1k
Govind Babu India 12 222 0.7× 88 0.4× 38 0.3× 147 1.2× 47 0.4× 90 524
Shuangshuang Fu United States 13 306 1.0× 68 0.3× 111 0.9× 40 0.3× 195 1.6× 40 898

Countries citing papers authored by Mengyang Di

Since Specialization
Citations

This map shows the geographic impact of Mengyang Di's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mengyang Di with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mengyang Di more than expected).

Fields of papers citing papers by Mengyang Di

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mengyang Di. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mengyang Di. The network helps show where Mengyang Di may publish in the future.

Co-authorship network of co-authors of Mengyang Di

This figure shows the co-authorship network connecting the top 25 collaborators of Mengyang Di. A scholar is included among the top collaborators of Mengyang Di based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mengyang Di. Mengyang Di is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Di, Mengyang, Matthew J. Maurer, & Christopher R. Flowers. (2025). End points and outcomes in follicular lymphoma: what should we measure, how, and why?. Blood. 146(15). 1802–1811.
2.
Epperla, Narendranath, Geoffrey Shouse, Jess Hatfield, et al.. (2025). Evaluation of real-world outcomes with zanubrutinib in patients with marginal zone lymphoma: Results from multicenter cohort study. Blood. 146(Supplement 1). 4534–4534.
3.
Poh, Christina, Xueyan Chen, Jenna Voutsinas, et al.. (2025). Impact of immunophenotype on clinical disease characteristics and outcomes in T‐cell prolymphocytic leukaemia. British Journal of Haematology. 207(5). 2143–2146.
4.
Poh, Christina, Jenna Voutsinas, Mazyar Shadman, et al.. (2025). Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas. Blood Advances. 9(15). 4037–4042. 1 indexed citations
5.
6.
Podoltsev, Nikolai A., Rong Wang, Rory M. Shallis, et al.. (2023). Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Medicine. 12(18). 18889–18900. 8 indexed citations
7.
Shallis, Rory M., Rong Wang, Amer M. Zeidan, et al.. (2023). Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances. 7(13). 3213–3224. 3 indexed citations
8.
Metayer, Catherine, Libby M. Morimoto, Joseph L. Wiemels, et al.. (2022). Hispanic Ethnicity Differences in Birth Characteristics, Maternal Birthplace, and Risk of Early-Onset Hodgkin Lymphoma: A Population-Based Case–Control Study. Cancer Epidemiology Biomarkers & Prevention. 31(9). 1788–1795.
9.
Di, Mengyang, Can Cui, Shalin Kothari, et al.. (2022). Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. Blood Advances. 6(11). 3339–3342. 6 indexed citations
10.
Di, Mengyang, Iris Isufi, Lohith Gowda, et al.. (2022). Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Advances. 7(5). 801–810. 38 indexed citations
11.
Di, Mengyang, Jessica B. Long, Iris Isufi, et al.. (2022). Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis. Blood. 140(Supplement 1). 10818–10819. 11 indexed citations
12.
Xia, Bin, Man Yang, Long H. Nguyen, et al.. (2021). Regular Use of Proton Pump Inhibitor and the Risk of Inflammatory Bowel Disease: Pooled Analysis of 3 Prospective Cohorts. Gastroenterology. 161(6). 1842–1852.e10. 53 indexed citations
13.
Patel, Kishan, Terri L. Parker, Mengyang Di, et al.. (2021). Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Leukemia & lymphoma. 62(11). 2777–2784. 6 indexed citations
14.
Gordon, Craig E., Marina Berenguer, Wahid Doss, et al.. (2019). Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. Annals of Internal Medicine. 171(7). 496–504. 14 indexed citations
15.
Di, Mengyang, et al.. (2018). Early Subcutaneous Emphysema Following Arthroscopy: A Case Report. 1 indexed citations
16.
Jadoul, Michel, Marina Berenguer, Wahid Doss, et al.. (2018). Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. Kidney International. 94(4). 663–673. 48 indexed citations
17.
Huang, Yafang, Jinling Tang, Wilson Tam, et al.. (2016). Comparing the Overall Result and Interaction in Aggregate Data Meta-Analysis and Individual Patient Data Meta-Analysis. Medicine. 95(14). e3312–e3312. 19 indexed citations
18.
Yang, Zu‐Yao, Mengyang Di, Jin-Qiu Yuan, et al.. (2015). The prognostic value of phosphorylated Akt in breast cancer: a systematic review. Scientific Reports. 5(1). 7758–7758. 55 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Deniz Tural Breakdown of academic impact, for papers by Shu Wang Breakdown of academic impact, for papers by Jonathan Klein Breakdown of academic impact, for papers by Eun‐Kee Song Breakdown of academic impact, for papers by Enes Erul Breakdown of academic impact, for papers by Mustafa Erman Breakdown of academic impact, for papers by Vincenzo Montesarchio Breakdown of academic impact, for papers by Vivek Kumar Breakdown of academic impact, for papers by Govind Babu Breakdown of academic impact, for papers by Shuangshuang Fu
Rankless by CCL
2026